Patents Assigned to Merck
  • Patent number: 10190043
    Abstract: A composition is provided, including one or more quantum dots and at least one organic emitter. Further, a formulation including the composition, a use of the formulation and a device comprising the composition or formulation is provided.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: January 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Junyou Pan, Niels Schulte, Thomas Eberle, Volker Hilarius
  • Patent number: 10188729
    Abstract: Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: January 29, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gu Danling, Amy M. Beebe
  • Patent number: 10189819
    Abstract: The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: January 29, 2019
    Assignees: Merck Sharp & Dohme, Corp., Mochida Paraceuticals Co., Ltd.
    Inventors: Ting Zhang, Yi-Heng Chen, Liangqin Guo, Alan Hruza, Tianying Jian, Bing Li, Dongfang Meng, Dann L. Parker, Edward C. Sherer, Harold B. Wood, Isao Sakurada
  • Patent number: 10190049
    Abstract: The invention relates to mesogenic media comprising one or more bimesogenic compounds, one or more nematogenic compound, one or more chiral compound and a compound of formula I, R11-A11-(Z12-A12)m-AG??I in which, the parameter A11, A12, Z12 and R11 have one of the meanings as given in claim 1, and to the use of these mesogenic media in liquid crystal devices and in particular in flexoelectric liquid crystal devices, as well as to liquid crystal devices comprising a liquid crystal medium according to the present invention.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: January 29, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Owain Ilyr Parri, Graziano Archetti, Simon Siemianowski, Izumi Saito, Rachel Tuffin
  • Patent number: 10193094
    Abstract: The present application relates to an organic electroluminescent device (OLED) which has an emitting layer comprising a compound having a small difference between the energies of the S1 and T1 states, and in which certain conditions apply to the HOMO and LUMO energy levels of the emitting layer and the layers between the anode and the emitting layer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: January 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Amir Hossain Parham, Christof Pflumm, Anja Jatsch, Joachim Kaiser
  • Patent number: 10193079
    Abstract: The present application relates to a compound of a formula (I) which comprises a benzene group that is substituted with a group selected from carbazole derivatives and bridged amines and with an electron attracting group, wherein the two groups are located in the ortho-position in relation to one another. The present application further relates to the use of the compound of the formula (I) in an electronic device, and to a method of producing the compound of the formula (I).
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: January 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Amir Hossain Parham, Christof Pflumm, Anja Jatsch
  • Patent number: 10190048
    Abstract: The invention relates to a liquid-crystalline medium, preferably having a nematic phase and negative dielectric anisotropy, which comprises a) one or more compounds of formula I and b) one or more compounds selected from the group of compounds of the formulae II and III in which the parameters have the respective meanings indicated in claim 1, to the use thereof in an electro-optical display, particularly in an active-matrix display based on the VA, ECB, PALC, IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type, and to the use of the compounds of formula I for reduction of the dispersion of the birefringence of a liquid-crystalline medium which comprises one or more compounds of the formulae II and/or III.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: January 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Atsutaka Manabe, Sven Baran, Lars Lietzau, Brigitte Schuler
  • Patent number: 10188592
    Abstract: The present invention relates to the use of compounds of the formula (I) for the care, preservation or improvement of the general condition or appearance of the skin or hair, and to preparations comprising compounds of the formula (I).
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: January 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Christophe Carola, Tatjana Best
  • Patent number: 10189831
    Abstract: Compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: January 29, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kenneth L. Arrington, Yongxin Han, Yaozong Li, Yunfu Luo, Mehul Patel
  • Patent number: 10193695
    Abstract: A system and a method of receiving object data representing one or more discriminating characteristics of a physical object or group of physical objects is described herein. The method includes: processing the object data by means of a machine-learning-based object recognition process to obtain discriminating data representing one or more collision resistant virtual representations of the physical object or group of physical objects; comparing at least one of the discriminating data and an original hash value derived therefrom by application of a pre-determined cryptographic hash function thereto with corresponding reference data stored in one or more data repositories with restricted access; and, if said comparison with the reference data results in a match, outputting digitally signed identification data comprising said hash value.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: January 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Thomas Endress, Daniel Szabo, Frederic Berkermann
  • Publication number: 20190022115
    Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula (I) and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. The present invention also provides processes for the preparation of 4?-substituted nucleoside derivatives of Formula (I) and derivatives thereof.
    Type: Application
    Filed: September 16, 2016
    Publication date: January 24, 2019
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Limited
    Inventors: Vinay M. Girijavallabhan, Mark McLaughlin, Edward Cleator, Jongrock Kong, Andrew William Gibson, David R. Lieberman, Alejandro Dieguez Vazquez, Stephen Philip Keen, Michael J. Williams, Jeffrey C. Moore, Erika M. Milczek, Feng Peng, Kevin M. Belyk, Zhiguo Jake Song
  • Publication number: 20190023836
    Abstract: The invention relates to novel compounds containing one or more 1,3-dithiolo[4,5-d]phthalimide (“DTPI”) units, to methods for their preparation preparation and educts or intermediates used therein, to mixtures and formulations containing them, to the use of the compounds, mixtures and formulations as organic semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising these compounds, mixtures or formulations.
    Type: Application
    Filed: February 17, 2017
    Publication date: January 24, 2019
    Applicant: Merck Patent GmbH
    Inventors: Changsheng WANG, William MITCHELL, David SPARROWE
  • Publication number: 20190023685
    Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
    Type: Application
    Filed: December 16, 2016
    Publication date: January 24, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter DORSCH, Mathilde MUZERELLE, Lars BURGDORF, Margarita WUCHERER-PLIETKER, Paul CZODROWSKI, Christina ESDAR, Christos TSAKLAKIDIS
  • Publication number: 20190022336
    Abstract: The present invention relates to drug delivery systems that cannot be reloaded or reused and further include a passive safety shield system. The drug delivery devices described herein comprise a drug container comprising at least one bellow, wherein the at least one bellow comprises a first surface and an opposing second surface, wherein the first surface is comprised of a first Belleville spring and the opposing second surface is comprised of a second Belleville spring, wherein the second Belleville spring has a higher spring rate than the first Belleville spring; or a drug container extending between distal and proximal ends, and comprises a continuous change in cross section from proximal end to distal end; a needle, wherein the needle is in liquid communication with the drug container; a plunger extending between a proximal end and a distal end, wherein the plunger is in communication with the drug container and where upon axial movement of the punger, the drug container is compressed.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Peter A. Basile, Steven Carl Persak, Mikhail Gotliboym, Brad Britland, Stephen G. Miggels, Henry J. Mack, Jr., Oliver J. Sha
  • Publication number: 20190023791
    Abstract: The present invention provides methods of treating cancer in a human in need thereof comprising administering to the human: a therapeutically effective amount of a monoclonal antibody that binds to human OX40 comprising: (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1; (b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2; (c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3; (d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:7; (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:8; and (f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9; and a therapeutically effective amount of a monoclonal antibody that binds to human PD-1 comprising: (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:54; (b) a heavy chain variable region CDR2 comprising the amino acid
    Type: Application
    Filed: August 3, 2016
    Publication date: January 24, 2019
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, MERCK SHARP & DOHME CORP.
    Inventors: Axel HOOS, David KAUFMAN, Elaine PINHEIRO, Herbert STRUEMPER, Niranjan YANAMANDRA
  • Patent number: 10183935
    Abstract: Novel benzamide derivatives of formula (I) wherein W1, W2, R1 to R10 and X have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: January 22, 2019
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Thomas E. Richardson, Pandi Bharathi, Brian H. Heasley, Matthew G. Jenks, Robert J. Foglesong
  • Patent number: 10183994
    Abstract: The invention relates to anti-TNF? antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNF? antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 22, 2019
    Assignee: Merck Patent GmbH
    Inventors: Ralf Guenther, Stefan Becker, Laura Rhiel, Bjoern Hock, Christian Schroeter
  • Patent number: 10183968
    Abstract: Methods for preparing lyophilized pellets of biological materials are described. The pellets have a substantially spherical shape and are prepared by freezing droplets of a liquid composition of a desired biological material on a flat, solid surface, in particular, a surface that does not have any cavities, followed by lyophilizing the frozen droplets. These methods are useful for preparing lyophilized pellets having a high concentration of a desired biological material, in particular a therapeutic protein or vaccine, and which have a faster reconstitution time than lyophilized powder cakes prepared in vials.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: January 22, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Colleen Barr, Akhilesh Bhambhani, Robert Evans, Lynne Isopi, David Krah, Jennifer Kriss, Jessica Sinacola
  • Publication number: 20190016729
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Application
    Filed: September 17, 2018
    Publication date: January 17, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John Y.L. Chung, Kevin Campos, Edwards Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Publication number: 20190016955
    Abstract: The present application relates to mixtures which have liquid-crystalline properties. The application furthermore relates to the use of the mixtures in devices which regulate the transmission of light through an area element.
    Type: Application
    Filed: December 12, 2016
    Publication date: January 17, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Michael JUNGE, Ursula PATWAL, Peer KIRSCH